Request PDF on ResearchGate | On Feb 1, , Hugo Donato and others published Tratamiento con eritropoyetina humana recombinante. Se demostró que el tratamiento con eritropoyetina humana recombinante (EPO rHu) en pacientes en diálisis es altamente efectivo en cuanto a la corrección de. Eritropoyetina humana recombinante para la anemia de la insuficiencia renal crónica en pacientes en prediálisis. This is not the most recent version of this.
|Published (Last):||15 June 2005|
|PDF File Size:||5.61 Mb|
|ePub File Size:||17.10 Mb|
|Price:||Free* [*Free Regsitration Required]|
Eritropoyetina Humana Recombinante –
On the other hand, residual renal function was maintained longer in BEN patients than in those with other kidney diseases 34 and our BEN patients were shorter on hemodialysis treatment than non-BEN patients. Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis.
The pharmacokinetic parameters of Epo are presented in Table 3. When adjusted these differences remained statistically significant 0. NDT Plus ;2 Suppl 1: Population pharmacokinetics of darbepoetin alfa in peritoneal dialysis and non-dialysis patients with chronic kidney disease after single subcutaneous administration.
Nephrol Dial Transplant ; Results of laboratory analyses in examined patients CRP: The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous humaan to healthy subjects. The aim of this study was to compare the pharmacokinetics of beta-erythropoietin beta-Epo given subcutaneously to BEN patients and patients with other kidney diseases non-BEN and to evaluate the factors influencing beta-Epo kinetics.
Impact of elevated C-reactive protein levels on erythropoiesis stimulating agent ESA dose and responsiveness in hemodialysis patients. In addition, recently described mechanisms independent of the Epo receptor elimination pathway, 29 may also contribute to eritrkpoyetina Epo elimination in BEN patients.
Eritropoyetina Humana Recombinante Delta –
However, several authors reported no significant differences between anemia in BEN and other kidney diseases. N Engl J Med ; Among the remaining 96 patients 40 BEN and 56 others who met inclusion criteria, 10 with BEN and 14 with other kidney diseases were selected using systematic sampling i. Analysis of covariance ANCOVA was used to adjust these differences for patient characteristics that differed between groups: Erythropoietin Epo concentration was determined in all samples on the same day by chemiluminescent immunoassay for erythropoietin on an Immulite analyzer Siemens Healthcare Diagnostics.
A number of factors may contribute to insufficient hematopoietic response to ESAs: Therefore, not only the distribution by itself, but also the process of elimination and interaction directly with the Epo receptor on the red blood cell surface play an important role in increasing the values of Vd for Epo in comparison to its physiological distribution limited to extravascular space in the body.
It seems most likely that both native Epo and recombinant drugs are degraded following receptor-mediated uptake, mainly in the bone marrow.
Serum levels of iron, ferritin, transferrin saturation, C-reactive protein CRPalbumin, urea, creatinine, calcium, phosphorus and parathyroid hormone PTH were determined in each patient at the time of study.
We recently showed that BEN hemodialysis patients required a higher dose of recombinant human erythropoietin for maintaining the target hemoglobin level than patients with other kidney diseases.
The significance of differences between mean values for groups was calculated using the Mann-Whitney U test and Student’s t-test.
To view content sources and attributions, please refer to our editorial policy. Population pharmacokinetics of erythropoietin in critically ill subjects. Cellular trafficking and degradation of erythropoietin and novel erythropoiesis stimulating protein NESP. The relevant pharmacokinetic parameters were calculated after noncompartmental pharmacokinetic analysis using Kinetica software Thermo Scientific, ver.
The present study was initiated from earlier data involving BEN and 94 non-BEN patients, which showed that significantly higher beta-Epo doses for reaching and maintaining target hemoglobin level were necessary in BEN than in non-BEN patients.
Eritropoyetina Humana Recombinante Delta
Colombia Further information Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances. Recent studies were largely devoted to the pharmacokinetics of new ESAs 10,12,14 and were usually carried out in healthy persons.
Recpmbinante Anemia was described as a characteristic of Balkan endemic nephropathy BEN in early reports on the disease, 1,2 so Danilovic 3 included it among the criteria for diagnosis.
Renal function, protein excretion and pathology of Balkan endemic nephropathy. Available for Android and iOS devices. Beta-erythropoietin administration and blood sampling.
Eritropoyetina Humana Recombinante
J Am Soc Nephrol ;5: The prospective clinical study was performed according to good clinical practice and in accordance with the Declaration of Helsinki in three clinical centers. All patients were treated thrice weekly for h bystandard bicarbonate hemodialysis using polysulphone membrane erltropoyetina. The results were expressed as mean values with standard deviations.
Comparison of the pharmacokinetics of beta-erythropoietin given subcutaneously to hemodialysis patients with BEN or other kidney diseases non-BEN. Pavlovic-Kentera V, Djukanovic Lj.